Hosted on MSN1mon
William Blair starts Mersana stock with Outperform ratingThe analyst from William Blair highlighted that despite previous challenges, such as the discontinuation of Mersana's former lead program, upifitamab rilsodotin (UpRi), the company's next ...
Mersana Therapeutics announced promising Phase ... primarily offset by reduced costs related to clinical development activities for UpRi, a discontinued ADC candidate. General and administrative ...
March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics ... with manufacturing and clinical development activities for UpRi, reduced employee compensation expenses following the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results